A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection

Neurology

Volumn 51, Issue 6, 1998, Pages 1682-1688

  Kieburtz, K ^a   Simpson, D ^a,m   Yiannoutsos, C ^l   Max, M B ^a,k   Hall, C D ^a,j   Ellis, R J ^a,i   Marra, C M ^a,h   McKendall, R ^a,g   Singer, E ^a,f   Dal Pan, G J ^a,e   Clifford, D B ^a,d   Tucker, T ^a,c   Cohen, B ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l CASE WESTERN RESERVE UNIVERSITY   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; MEXILETINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; PAIN ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

EID: 0031701543     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.6.1682     Document Type: Article

References (34)

1. Hall CD, Snyder CR, Messenheimer JA, et al. Peripheral neuropathy in a cohort of human immunodeficiency virus-infected patients. Incidence and relationship to other nervous system dysfunction. Arch Neurol 1991;48:1273-1274.
2. So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome: prevalence and clinical features from a populationbased survey. Arch Neurol 1988;45:945-948.
3. Snider WD, Simpson DM, Nielson S, et al. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983;14:403-418.
4. Bailey RO, Baltch AL, Venkatesh R, Singh JK, Bishop MB. Sensory motor neuropathy associated with AIDS. Neurology 1988;38:886-891.
5. Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and ARC. Neurology 1988;38:794796.
6. Barohn RJ, Gronseth GS, LeForce BR, et al. Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol 1993;50: 167-171.
7. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: multicenter AIDS Cohort Study. Neurology 1994;44:1892-1900.
8. Brannagan TH, Nuovo GJ, Hays AP, Latov N. Human immunodeficiency virus infection of dorsal root ganglion neurons detected by polymerase chain reaction in situ hybridization. Ann Neurol 1997;42:368-372.
9. Bradley WG, Verma A. Painful vasculitic neuropathy in HIV-1 infection: relief of pain with prednisone therapy. Neurology 1996;47:1446-1451.
10. Simpson DM, Dorfman D, Olney RK, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology 1996;47:1254-1259.
11. Max MB, Culnane M, Schäfer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-596.
12. Vrethem M, Boivie J, Arnqvist H, et al. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and non-diabetics. Clin J Pain 1997; 13:313-323.
13. Basbaum AI and Fields HL. Endogenous pain control mechanisms: review and hypothesis. Ann Neurol 1978;4:451-462.
14. Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 1992;48:261-268.
15. Jett MF, McGuirk J, Waligora D, Hunter JC. The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Pain 1997;69:161-169.
16. Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988;l(8575-6): 9-11.
17. Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992;15:1550-1555.
18. Chabal C, Jacobson L, Mariano A, Chaney E, Britell CW. The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiology 1992;76:513-517.
19. McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in the treatment of chronic pain. Anaesthesia 1993;48:281-285.
20. Sindrup SH, Gram LF, Skjold T, Froland A, Beck-Nielsen H. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 1990; 47:509-515.
21. Gracely RH, McGrath P, Dubner R. Ratio scales of sensory and affective verbal pain descriptors. Pain 1978;5:5-18.
22. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-1256.
23. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. 3rd ed. Glenview, IL: American Pain Society, 1992.
24. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556.
25. Shlay J, Chaloner K, Max M, et al. A randomized, placebocontrolled trial of standardized acupuncture regimen or ami-
26. triptyline for pain caused by HIV-associated peripheral neuropathy. JAMA 1998;280:1590-1595.
27. Tyor WR, Wesselingh SL, Griffin JW, McArthur JC, Griffin DE. Unifying hypothesis for the pathogenesis of HIVassociated dementia complex, vacuolar myelopathy, and sensory neuropathy. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:379-388.
28. Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. J Pain Symptom Manage 1996;12: 161-167.
29. Sangameswaran L, Fish LM, Koch BD, et al. A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia. J Biol Chem 1997;272:14805-14809.
30. Cherny NI, Thaler HT, Firedlander-Klar H, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology 1994;44:857-861.
31. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991;41:1024-1028.
32. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine: a double-blind, crossover comparison with morphine and placebo. Pain 1994;58: 347-354.
33. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. Highdose oral dextromethorphan in diabetic neuropathy pain and post-herpetic neuralgia: a double-blind, placebo controlled study. Neurology 1997;48:1212-1218.
34. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 1996;12:56-58.